Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-122A for ventilator-associated pneumonia
2025-521533-85-00Phase 2Authorised
- Sponsor
- TechnoPhage
- Start
- Sep 2025
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in ventilator-associated pneumonia (VAP) and Pseudomonas pneumonia comparing TP-122A plus standard of care with Standard of care alone (2 arms). Primary endpoint: Safety and tolerability. Planned start Sep 2025; status: authorised.
02
Drugs
TP-122A
03
Conditions
ventilator-associated pneumonia (VAP)Pseudomonas pneumonia
Beyond the preview
Go deeper on 2025-521533-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521533-85-00.